Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus...

Area of Science:

• Transplantation immunology
• Infectious diseases
• Cardiothoracic surgery

Background:

• Hepatitis C virus (HCV) infection historically precluded organ donation.
• Recent advancements in direct-acting antiviral (DAAV) therapies have transformed HCV treatment outcomes.
• This has opened possibilities for utilizing organs from HCV-positive donors.

Purpose of the Study:

• To provide consensus statements on the use of HCV-positive donors for heart and lung transplantation.
• To outline the current state of knowledge and expertise in this emerging area.
• To guide the transplant community in this evolving practice.

Main Methods:

• Review of current literature and clinical experience.
• Expert panel discussions and consensus building.
• Development of guidelines for donor selection and recipient management.

Main Results:

• HCV-positive donors can be safely utilized for heart and lung transplantation.
• DAAV therapy can effectively treat HCV infection in transplant recipients.
• This practice expands the donor pool, offering life-saving opportunities.

Conclusions:

• The use of HCV-positive donors is a viable strategy to increase organ availability for heart and lung transplantation.
• Careful patient selection and management protocols are essential.
• This field is rapidly evolving, requiring ongoing updates to guidelines.